Affinage

LRRFIP1

Leucine-rich repeat flightless-interacting protein 1 · UniProt Q32MZ4

Length
808 aa
Mass
89.3 kDa
Annotated
2026-06-10
36 papers in source corpus 21 papers cited in narrative 21 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 7/7 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

LRRFIP1 (also termed GCF2) is a pleiotropic nucleic acid-binding scaffold and transcriptional regulator that links cytosolic nucleic acid sensing, Wnt/β-catenin signaling, and cytoskeletal organization (PMID:20453844, PMID:16199883, PMID:28322931). In innate immunity it binds exogenous double-stranded RNA and DNA and activates β-catenin, which engages the C-terminal domain of IRF3 and recruits p300 to the IFN-β enhanceosome to amplify type I interferon production in response to viral and bacterial challenge (PMID:20453844). Independently of its sensing role, LRRFIP1/GCF2 functions as a sequence-specific transcriptional repressor, binding GC-rich elements of the EGFR promoter through a DNA-binding/repression domain mapped to residues 429–528 (PMID:14522076) and occupying the TNF-α −308 promoter site to keep the gene silent, with derepression occurring when it is displaced by activating factors (PMID:16199883); this repressive activity at the TNF locus is extended through direct binding to upstream long noncoding RNAs that template a repressive complex on chromatin (PMID:24567534). Structurally, its FLI-interacting domain forms a parallel homodimeric coiled coil, and longer constructs assemble into higher-order oligomers, providing the multimerization framework for its activities (PMID:23099021); isoform-specific behavior follows from this architecture, with LRRFIP1-Iso1 acting as the strongest enhancer of canonical Wnt/β-catenin transcription via an N-terminal domain bearing critical tryptophans W76/W82 and obligate homodimerization, while shared C-terminal sequence dictates nuclear versus cytoplasmic isoform distribution (PMID:28322931). Through β-catenin and Dishevelled (DVL2/DVL3) engagement it modulates Wnt-dependent proliferation and survival and drives epithelial-mesenchymal transition by acting on the β-catenin destruction complex (PMID:26047573, PMID:40420163). LRRFIP1 also controls cytoskeletal and adhesion programs: it interacts with the actin-remodeling proteins Flightless-1 and Drebrin in platelets and promotes thrombus formation and αIIbβ3 integrin-dependent platelet activation (PMID:20833976, PMID:31258662), and it acts upstream of RhoA to govern actin/filamin architecture, cell migration, and invasion (PMID:22571463, PMID:22750095). Additional roles in adipocyte differentiation via repression of E2F6 and downstream C/EBPα (PMID:41224206) and in tumor-associated macrophage M2 polarization via PI3K/AKT signaling (PMID:41612403) mark it as a broadly acting regulatory node.

Mechanistic history

Synthesis pass · year-by-year structured walk · 17 steps
  1. 2003 Medium

    Established LRRFIP1/GCF2 as a sequence-specific transcriptional repressor by mapping a discrete DNA-binding and repression domain on the EGFR promoter, defining its earliest known molecular function.

    Evidence Deletion mutagenesis, promoter-reporter assays, and subcellular fractionation

    PMID:14522076

    Open questions at the time
    • Did not resolve whether repression is direct or requires cofactor complexes
    • Endogenous physiological context of EGFR repression untested
  2. 2005 High

    Showed direct, sequence-specific DNA binding to the TNF-α −308 site and a switch-like repressor role, distinguishing TNF-competent from non-competent cells.

    Evidence Affinity purification, ChIP, EMSA, and surface plasmon resonance

    PMID:16199883

    Open questions at the time
    • Repressive complex composition at the locus not defined
    • How LRRFIP1 is displaced to permit activation not resolved
  3. 2010 High

    Defined a novel innate-immune function: LRRFIP1 senses cytosolic dsRNA/dsDNA and routes signal through β-catenin to the IRF3/p300 IFN-β enhanceosome, connecting nucleic acid binding to interferon induction.

    Evidence Reciprocal Co-IP, siRNA/shRNA knockdown, reporter assays, and nucleic acid binding assays in macrophages challenged with VSV and Listeria

    PMID:20453844

    Open questions at the time
    • Structural basis of dsRNA/dsDNA recognition not defined
    • Relationship between sensing and transcriptional repressor activity unclear
  4. 2010 Medium

    Placed LRRFIP1 in the platelet cytoskeleton via interactions with actin-remodeling proteins and demonstrated an in vivo role in thrombus formation.

    Evidence Proteomic interactome (Flightless-1, Drebrin) and morpholino knockdown in zebrafish

    PMID:20833976

    Open questions at the time
    • Direct binding interfaces with Flightless-1/Drebrin not mapped
    • Mechanism linking cytoskeletal role to thrombosis not detailed
  5. 2010 Medium

    Provided localization and post-translational evidence that LRRFIP1 is serine-phosphorylated and traffics to dsRNA-containing lysosomal structures upon stimulation.

    Evidence Western blot for serine phosphorylation and immunofluorescence colocalization with labeled dsRNA in monocytes

    PMID:21102652

    Open questions at the time
    • Kinase responsible for phosphorylation not identified
    • Functional consequence of lysosomal colocalization untested
  6. 2012 Medium

    Connected LRRFIP1/GCF2 to RhoA-dependent cytoskeletal and drug-resistance phenotypes, showing it acts upstream of RhoA and through LARG to drive integrin-dependent migration and metastasis.

    Evidence Gain/loss-of-function with RhoA/actin/MRP1 readouts plus an in vivo colorectal metastasis model and RhoA-LARG interaction analysis

    PMID:22571463 PMID:22750095

    Open questions at the time
    • Whether RhoA regulation is transcriptional or post-translational not fully resolved
    • Direct vs. indirect control of LARG-RhoA coupling unclear
  7. 2012 High

    Resolved the oligomerization architecture by solving the FLI-interacting domain as a parallel homodimeric coiled coil, with longer constructs forming higher-order oligomers.

    Evidence X-ray crystallography and solution biophysics

    PMID:23099021

    Open questions at the time
    • No full-length structure or DNA/RNA-bound complex
    • Functional role of higher-order oligomers not directly tested
  8. 2014 Medium

    Extended TNF repression to an RNA-scaffolded mechanism, showing LRRFIP1 binds upstream long noncoding RNAs that recruit it to chromatin as part of a repressive complex.

    Evidence RNA-IP, ChIP, and RNA knockdown/overexpression

    PMID:24567534

    Open questions at the time
    • Other components of the repressive complex not fully cataloged
    • RNA-binding domain within LRRFIP1 not mapped
  9. 2014 Medium

    Demonstrated isoform- and tissue-specific cytoplasmic localization driving β-catenin/Akt/mTOR activation and GLT-1 regulation in CNS ischemia.

    Evidence qPCR, immunohistochemistry, fractionation, and pathway Western blot in ischemia models

    PMID:24637094

    Open questions at the time
    • Direct molecular targets in the β-catenin/Akt/mTOR axis not defined
    • Causality between LRRFIP1 and GLT-1 regulation not mechanistically dissected
  10. 2015 Medium

    Linked LRRFIP1 to EMT control by acting on the β-catenin destruction complex to govern β-catenin phosphorylation and nuclear localization in cancer cells.

    Evidence siRNA knockdown with EMT markers, β-catenin fractionation, and migration/invasion assays in pancreatic and lung cancer lines

    PMID:26047573

    Open questions at the time
    • Direct interaction with destruction complex components not shown
    • Distinction between sensing-independent and Wnt-dependent roles unclear
  11. 2017 High

    Defined the structure-function determinants of Wnt enhancement: Iso1 is the strongest activator, requiring W76/W82 and coiled-coil-mediated homodimerization, with C-terminal sequence dictating nuclear vs cytoplasmic isoform distribution.

    Evidence Topflash reporter, site-directed mutagenesis (W76A/W82A), immunofluorescence localization, and Co-IP oligomerization

    PMID:28322931

    Open questions at the time
    • Direct binding partner engaged by the W76/W82 surface not identified
    • How isoform localization tunes downstream outputs not resolved
  12. 2019 Medium

    Genetic knockout established that LRRFIP1 is required for αIIbβ3 integrin expression and agonist-induced platelet agglutination, formalizing its in vivo platelet role.

    Evidence LRRFIP1 knockout mouse, aggregometry, and flow cytometry for active αIIbβ3

    PMID:31258662

    Open questions at the time
    • Mechanism by which LRRFIP1 controls αIIbβ3 levels not defined
    • Link to earlier cytoskeletal interactome not directly tested
  13. 2020 Low

    Identified DAPK1 as a stress-induced LRRFIP1 interactor in neurons under oxygen/glucose deprivation, extending its interaction network into oxidative stress responses.

    Evidence LC-MS/MS, Co-IP and reverse Co-IP in primary cortical neurons under OGD/erastin

    PMID:33265962

    Open questions at the time
    • Functional consequence of the LRRFIP1–DAPK1 interaction not tested
    • Single Co-IP validation of an MS hit without structural mapping
  14. 2021 Medium

    Connected LRRFIP1 to chemoresistance by showing its silencing sensitizes pancreatic cancer cells to gemcitabine through Rac-dependent JNK/c-Jun activation.

    Evidence siRNA knockdown, phospho-Western blot, Rac inhibitor epistasis, and viability/caspase assays

    PMID:33707114

    Open questions at the time
    • Direct molecular link between LRRFIP1 and Rac not established
    • Whether effect generalizes beyond pancreatic cancer untested
  15. 2025 Medium

    Identified Dishevelled proteins (DVL2/DVL3) as Wnt-pathway partners through which LRRFIP1 synergistically amplifies β-catenin signaling and proliferation/survival in MDS cells.

    Evidence Transcriptome sequencing, dual luciferase reporter, co-overexpression synergy, and proliferation/apoptosis assays

    PMID:40420163

    Open questions at the time
    • Direct LRRFIP1–DVL binding inferred from synergy, not biochemically mapped
    • Domain mediating DVL engagement not defined
  16. 2025 Medium

    Extended transcriptional repressor activity to adipogenesis, showing LRRFIP1 binds the E2F6 promoter to suppress E2F6 and downstream C/EBPα, inhibiting white adipocyte differentiation.

    Evidence ChIP, luciferase promoter assay, gain/loss-of-function in C3H10T1/2 cells, and diet-induced obesity mouse model

    PMID:41224206

    Open questions at the time
    • Cofactors at the E2F6 promoter not identified
    • Relation to GC-rich binding seen at EGFR/TNF promoters not tested
  17. 2026 Medium

    Defined a role in the tumor microenvironment, with LRRFIP1 promoting M2-like macrophage polarization via PI3K/AKT and TGF-β receptor signaling.

    Evidence siRNA knockdown in TAMs, flow cytometry, cytokine ELISA, PI3K inhibitor epistasis, and in vivo tumor/metastasis models

    PMID:41612403

    Open questions at the time
    • Direct molecular targets upstream of PI3K/AKT not identified
    • Whether nucleic acid sensing contributes to this role untested

Open questions

Synthesis pass · forward-looking unresolved questions
  • How a single protein integrates cytosolic nucleic acid sensing, GC-rich/lncRNA-templated transcriptional repression, and Wnt/β-catenin enhancement into a coherent regulatory logic — and which activities are isoform-, tissue-, or stimulus-specific — remains unresolved.
  • No full-length structure bound to nucleic acid or partners
  • Domain assignment of RNA binding vs DNA binding vs partner engagement incomplete
  • Isoform-specific division of labor across tissues not systematically mapped

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 4 GO:0003677 DNA binding 3 GO:0003723 RNA binding 2 GO:0008092 cytoskeletal protein binding 2 GO:0060090 molecular adaptor activity 2 GO:0140299 molecular sensor activity 1
Localization
GO:0005829 cytosol 3 GO:0005634 nucleus 2 GO:0005856 cytoskeleton 2 GO:0005764 lysosome 1
Pathway
R-HSA-74160 Gene expression (Transcription) 4 R-HSA-162582 Signal Transduction 3 R-HSA-109582 Hemostasis 2 R-HSA-168256 Immune System 2
Partners
CTNNB1DAPK1DBN1DVL2DVL3EP300FLIIIRF3

Evidence

Reading pass · 21 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2010 LRRFIP1 functions as a cytosolic nucleic acid sensor that binds exogenous double-stranded RNA and double-stranded DNA, then interacts with β-catenin to promote its activation; activated β-catenin binds the C-terminal domain of IRF3 and recruits the acetyltransferase p300 to the IFN-β enhanceosome, thereby increasing IFN-β production in macrophages in response to VSV and Listeria monocytogenes. Co-immunoprecipitation, knockdown (siRNA/shRNA), overexpression, reporter assays, nucleic acid binding assays in macrophages Nature immunology High 20453844
2003 GCF2/LRRFIP1 is a transcriptional repressor of the EGFR promoter; deletion mutagenesis mapped the DNA-binding and repression domain to amino acids 429–528, and GCF2 also suppresses AP2-mediated activation of the EGFR promoter. GCF2 protein was detected in both nuclear and cytoplasmic compartments. Deletion mutagenesis, promoter-reporter assays, subcellular fractionation/Western blot, Northern blot Biochimica et biophysica acta Medium 14522076
2005 GCF2/LRRFIP1 binds the TNF-α −308 promoter site and acts as a transcriptional repressor; it occupies the −308 site in cells that do not produce TNF-α, whereas Ets-1 binds this site in TNF-α-competent cells. Active transcription is additionally accompanied by NF-κB and c-Jun binding to the proximal promoter. Affinity purification of binding proteins, chromatin immunoprecipitation (ChIP), electrophoretic mobility shift assay (EMSA), surface plasmon resonance Molecular and cellular biology High 16199883
2010 In human platelets, LRRFIP1 functions as a component of the platelet cytoskeleton, where it interacts with the actin-remodeling proteins Flightless-1 and Drebrin, as identified by proteomic analysis of LRRFIP1-interacting proteins. Morpholino-based silencing in zebrafish demonstrated a significant positive regulatory role for lrrfip1 in thrombus formation. Proteomic co-immunoprecipitation (LRRFIP1 interactome), morpholino knockdown in Danio rerio, correlation analysis of platelet RNA expression Blood Medium 20833976
2010 LRRFIP1 is phosphorylated on serine residues, and this phosphorylation is altered by poly I:C and nicotine stimulation. Upon dsRNA stimulation, LRRFIP1 colocalizes with labeled dsRNA in monocyte lysosomal structures, whereas it does not colocalize with lysosomes lacking dsRNA. Western blot for serine phosphorylation, immunofluorescence colocalization with labeled dsRNA and lysosomal markers Biochemistry and cell biology Medium 21102652
2012 GCF2/LRRFIP1 acts upstream of the small GTPase RhoA as a transcriptional repressor; overexpression of GCF2 results in loss of RhoA expression, disruption of the actin/filamin network, internalization of membrane transporter MRP1 from the cell surface into cytoplasm, increased doxorubicin accumulation, and increased cisplatin resistance. siRNA knockdown of GCF2 in cisplatin-resistant cells reactivated RhoA, restored actin microfilament structure, and relocated MRP1 to the cell surface. GCF2 overexpression and siRNA knockdown, Western blot for RhoA and MRP1, immunofluorescence for actin/filamin/MRP1 localization, drug sensitivity assays Molecular pharmaceutics Medium 22571463
2012 GCF2/LRRFIP1 promotes colorectal cancer metastasis by regulating RhoA interaction with the RGS domain of LARG (Leukemia Associated RhoGEF), thereby driving integrin-dependent RhoA activation, cell adhesion, migration, and invasion. Stable shRNA knockdown in HT-29 cells, in vivo spleen injection metastasis model (SCID mice), fibronectin-induced adhesion/migration/invasion assays, RhoA-LARG interaction analysis Cancer letters Medium 22750095
2012 The FLI-interacting domain of LRRFIP1 forms a classic parallel homodimeric coiled coil with 10 heptad repeats and 22 helical turns, confirmed as a dimer in solution; a longer construct spanning the coiled-coil and DNA-binding domains assembles into higher-order oligomers in solution. X-ray crystallography of LRRFIP1 coiled-coil domain, solution biophysics (confirming dimer/oligomer state) Journal of structural biology High 23099021
2013 LRRFIP1 induces vascular smooth muscle cell (VSMC) proliferation and increases phosphorylation of ERK; miR-132 blocks VSMC proliferation by directly targeting and downregulating LRRFIP1 via its 3′-UTR. miR-132 mimic/antagomir transfection, luciferase reporter assay with LRRFIP1 3′-UTR, Western blot for p27/SM α-actin/Bcl2, ERK phosphorylation assay, carotid artery injury model in rat Atherosclerosis Medium 23880186
2014 LRRFIP1 binds directly to long noncoding RNAs upstream of the TNF gene and serves as part of a repressive complex assembled on these noncoding RNAs; knockdown of the noncoding RNAs reduced LRRFIP1 binding to both RNA targets and chromatin, leading to TNF derepression, while overexpression of the noncoding RNAs recruited repressor proteins including LRRFIP1 to the locus. RNA immunoprecipitation, ChIP, RNA knockdown and overexpression, five complementary identification methods for noncoding RNAs Journal of immunology Medium 24567534
2014 In rat cortex after cerebral ischemia, Lrrfip1 (the main isoform) is upregulated from acute to late phases and localizes to the cytoplasm of neurons and astrocytes in the peri-infarct area. In astrocytes, Lrrfip1 activates β-catenin, Akt, and mTOR signaling and positively regulates expression of the glutamate transporter GLT-1. qPCR, immunohistochemistry, subcellular fractionation, in vivo and in vitro ischemia models, Western blot for pathway activation Neuroscience Medium 24637094
2015 LRRFIP1 silencing in pancreatic and lung cancer cells reverses the epithelial-mesenchymal transition (EMT), evidenced by increased E-cadherin and decreased vimentin; mechanistically, LRRFIP1 silencing upregulates phosphorylation of β-catenin and decreases its nuclear localization by targeting the β-catenin destruction complex, while increasing β-catenin and E-cadherin in the plasma membrane fraction and inhibiting migration and invasion. siRNA knockdown, Western blot for EMT markers, subcellular fractionation for β-catenin localization, migration/invasion assays Cancer letters Medium 26047573
2015 LRRFIP1 overexpression in hepatocytes increases IFN-β expression (with or without HCV infection) and inhibits HCV replication, establishing a role for LRRFIP1-mediated type I interferon induction in controlling HCV infection. LRRFIP1 overexpression in Huh7/Huh7.5.1 cells, qRT-PCR and Western blot for IFN-β, HCV replication assay Hepatitis monthly Low 26045710
2017 Among LRRFIP1 isoforms, LRRFIP1-Iso1 is the strongest enhancer of the canonical Wnt/β-catenin transcription pathway; this activity requires a specific N-terminal domain harboring two critical tryptophan residues (W76, W82) and depends on LRRFIP1-Iso1 homodimerization governed by its specific coiled-coil domain. LRRFIP1-Iso1 and -Iso2 are primarily nuclear due to their shared C-terminal domain, whereas Iso3, -4, and -5 are primarily cytoplasmic and form homo/hetero-multimers. Topflash β-catenin reporter assay, site-directed mutagenesis (W76A, W82A), subcellular localization by immunofluorescence, co-immunoprecipitation for oligomerization, expression profiling Biochimica et biophysica acta. Molecular cell research High 28322931
2019 LRRFIP1 expression triggers platelet agglutination by enhancing αIIbβ3 integrin expression; LRRFIP1 knockout in mice significantly decreased αIIbβ3 levels and inhibited platelet agglutination in response to collagen, thrombin, and convulxin. LRRFIP1 knockout mouse model, platelet aggregation apparatus, flow cytometry for active αIIbβ3 Experimental and therapeutic medicine Medium 31258662
2020 LRRFIP1 is a novel interactor of DAPK1 (Death-Associated Protein Kinase 1) in neurons exposed to oxygen/glucose deprivation (OGD); LRRFIP1 protein levels are increased by pro-oxidant conditions (OGD or the ferroptosis inducer erastin), and the LRRFIP1–DAPK1 interaction was confirmed by reverse Co-IP. Co-immunoprecipitation (Co-IP and reverse Co-IP), LC-MS/MS proteomics, Western blot, OGD and erastin treatment of primary rat cortical neurons Antioxidants Low 33265962
2021 LRRFIP1 silencing in pancreatic cancer cells sensitizes them to gemcitabine by activating the JNK/c-Jun signaling axis; gemcitabine-induced JNK and c-Jun phosphorylation are increased in LRRFIP1 knockdown cells, and this JNK/c-Jun activation depends on Rac activity, as Rac inhibition diminishes the effect. siRNA knockdown, caspase activity assay, phospho-Western blot for JNK/c-Jun, Rac inhibitor treatment, cell viability assays Pancreatology Medium 33707114
2024 GCF2/LRRFIP1 mediates nicotine-induced HCC cancer stemness and progression by activating the Wnt/β-catenin/SOX2 signaling pathway; nicotine stabilizes GCF2 protein levels, and silencing GCF2 reduces nicotine-induced stemness and progression. GCF2 siRNA knockdown, overexpression, Western blot for Wnt/β-catenin/SOX2 pathway components, cancer stemness assays Ecotoxicology and environmental safety Low 38218109
2025 LRRFIP1 enhances canonical Wnt/β-catenin signaling in MDS cells by binding to DVL2 and DVL3 (Dishevelled proteins); LRRFIP1 and Dvl synergistically increase Wnt pathway activity, upregulate β-catenin, Dvl2, Dvl3, BCL-2, and CyclinD1, and promote MDS cell proliferation while inhibiting apoptosis. mRNA transcriptome sequencing, dual luciferase reporter assay, Western blot, co-overexpression experiments (LRRFIP1/Dvl3), CCK8, Annexin-V apoptosis assays Journal of translational medicine Medium 40420163
2025 LRRFIP1 inhibits white adipocyte differentiation by binding to the E2F6 promoter and suppressing E2F6 transcription, which in turn downregulates C/EBPα; silencing LRRFIP1 inhibits adipogenic differentiation in C3H10T1/2 cells and reduces differentiation biomarker expression, while overexpression has the opposite effect. Chromatin immunoprecipitation (ChIP), luciferase promoter assay, qRT-PCR, Western blot, C3H10T1/2 adipogenic differentiation assay, diet-induced obesity mouse model Diabetes & metabolism journal Medium 41224206
2026 In tumor-associated macrophages (TAMs), LRRFIP1 promotes M2-like macrophage polarization via the PI3K/AKT signaling pathway; LRRFIP1 knockdown suppresses M2 phenotype and related cytokine expression, and inhibition of the PI3K pathway or TGF-β receptor abolishes further effects of LRRFIP1 knockdown. siRNA knockdown in TAMs, flow cytometry, Western blot for PI3K/AKT, ELISA for cytokines, Transwell invasion assay, in vivo tumor/metastasis models, PI3K inhibitor epistasis experiment Journal of translational medicine Medium 41612403

Source papers

Stage 0 corpus · 36 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2010 The cytosolic nucleic acid sensor LRRFIP1 mediates the production of type I interferon via a beta-catenin-dependent pathway. Nature immunology 318 20453844
2009 MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme. Brain research 169 19559015
2013 The microRNA miR-132 targets Lrrfip1 to block vascular smooth muscle cell proliferation and neointimal hyperplasia. Atherosclerosis 77 23880186
2010 Transcription profiling in human platelets reveals LRRFIP1 as a novel protein regulating platelet function. Blood 75 20833976
2005 GCF2/LRRFIP1 represses tumor necrosis factor alpha expression. Molecular and cellular biology 65 16199883
2015 Silencing of LRRFIP1 reverses the epithelial-mesenchymal transition via inhibition of the Wnt/β-catenin signaling pathway. Cancer letters 45 26047573
2012 GCF2/LRRFIP1 promotes colorectal cancer metastasis and liver invasion through integrin-dependent RhoA activation. Cancer letters 37 22750095
2003 GCF2: expression and molecular analysis of repression. Biochimica et biophysica acta 33 14522076
2019 Multidisciplinary Roles of LRRFIP1/GCF2 in Human Biological Systems and Diseases. Cells 29 30709060
2019 MiR-215-5p inhibits the inflammation injury in septic H9c2 by regulating ILF3 and LRRFIP1. International immunopharmacology 28 31806569
2013 A variant in the LRRFIP1 gene is associated with adiposity and inflammation. Obesity (Silver Spring, Md.) 28 23505185
2012 The transcription factor GCF2 is an upstream repressor of the small GTPAse RhoA, regulating membrane protein trafficking, sensitivity to doxorubicin, and resistance to cisplatin. Molecular pharmaceutics 23 22571463
2014 Noncoding RNAs and LRRFIP1 regulate TNF expression. Journal of immunology (Baltimore, Md. : 1950) 22 24567534
2014 Characterization of Gcf2/Lrrfip1 in experimental cerebral ischemia and its role as a modulator of Akt, mTOR and β-catenin signaling pathways. Neuroscience 22 24637094
2010 Characterization of LRRFIP1. Biochemistry and cell biology = Biochimie et biologie cellulaire 22 21102652
2017 The alternatively spliced LRRFIP1 Isoform-1 is a key regulator of the Wnt/β-catenin transcription pathway. Biochimica et biophysica acta. Molecular cell research 15 28322931
2014 Knockdown of GCF2/LRRFIP1 by RNAi causes cell growth inhibition and increased apoptosis in human hepatoma HepG2 cells. Asian Pacific journal of cancer prevention : APJCP 13 24761896
2012 Crystal structure of the dimeric coiled-coil domain of the cytosolic nucleic acid sensor LRRFIP1. Journal of structural biology 13 23099021
2020 A novel LRRFIP1-ALK fusion in inflammatory myofibroblastic tumor of hip and response to crizotinib. Investigational new drugs 12 32915420
2020 Comparative Proteomics Unveils LRRFIP1 as a New Player in the DAPK1 Interactome of Neurons Exposed to Oxygen and Glucose Deprivation. Antioxidants (Basel, Switzerland) 12 33265962
2014 Higher LRRFIP1 expression in glioblastoma multiforme is associated with better response to teniposide, a type II topoisomerase inhibitor. Biochemical and biophysical research communications 12 24690174
2015 LRRFIP1 Inhibits Hepatitis C Virus Replication by Inducing Type I Interferon in Hepatocytes. Hepatitis monthly 11 26045710
2021 Silencing of LRRFIP1 enhances the sensitivity of gemcitabine in pancreatic cancer cells by activating JNK/c-Jun signaling. Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 8 33707114
2023 Acute myeloid leukemia with LRRFIP1::FGFR1 rearrangement and a complex karyotype. Cancer genetics 6 37597337
2019 LRRFIP1 expression triggers platelet agglutination by enhancing αIIbβ3 expression. Experimental and therapeutic medicine 5 31258662
2022 Copy number variations of LRRFIP1 gene and the relationship with growth traits in four Chinese sheep. Animal biotechnology 4 36170043
2013 Anti-thrombosis effect of LRRFIP1 shRNA lentivirus in a mouse model of deep vein thrombosis. Thrombosis research 4 23751182
2024 GCF2 mediates nicotine-induced cancer stemness and progression in hepatocellular carcinoma. Ecotoxicology and environmental safety 3 38218109
2024 The clinical significance and oncogenic function of LRRFIP1 in pancreatic cancer. Discover oncology 3 38634978
2023 lncRNA UCA1 regulates miR-132/Lrrfip1 axis to promote vascular smooth muscle cell proliferation. Open medicine (Warsaw, Poland) 3 37533737
2025 Analysis of TNS3-203 and LRRFIP1-211 Transcripts as Oral Cancer Biomarkers. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 1 39888120
2025 First report of B-lymphoblastic leukemia harboring LRRFIP1::FGFR1 fusion: expanding the clinical spectrum of myeloid/lymphoid neoplasms with tyrosine kinase gene fusions. Annals of hematology 1 40586868
2026 Tumor-associated macrophage-specific LRRFIP1 promotes M2 macrophage polarization and progression of colorectal cancer via activation of the PI3K pathway. Journal of translational medicine 0 41612403
2026 Epithelioid Fibrous Histiocytoma with LRRFIP1::ALK Fusion and Smooth Muscle Hyperplasia. International journal of surgical pathology 0 42087749
2025 LRRFIP1 enhances the Wnt/β-catenin pathway by binding to DVLs in myelodysplastic syndrome. Journal of translational medicine 0 40420163
2025 LRRFIP1 Inhibits White Adipocyte Differentiation by Suppressing the E2F6/C/EBPα Axis. Diabetes & metabolism journal 0 41224206

Missed literature

Know a paper Affinage missed for LRRFIP1? Flag it for the maintainers and the community.

No submissions yet.